Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ferritin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    508 result(s) found for: Ferritin. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002583-14 Sponsor Protocol Number: CICL670A2201 Start Date*: 2016-11-25
    Sponsor Name:Novartis Pharmaceuticals Corp
    Full Title: A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients...
    Medical condition: Sickle Cell Disease/ Iron Overload
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000995-88 Sponsor Protocol Number: V00305SB301 Start Date*: 2016-04-12
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Study of efficacy and safety of V0305 solution in children suffering from Iron Deficiency Anaemia (IDA). Phase 3, multicentre, single arm open-label study
    Medical condition: Iron Deficiency Anaemia
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-003953-16 Sponsor Protocol Number: CICL670A2409 Start Date*: 2007-05-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A one-year, open-label, single arm, multi-centre trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload
    Medical condition: Transfusional iron overload
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) DK (Completed) BE (Completed) DE (Completed) NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000201-84 Sponsor Protocol Number: AT2020_01 Start Date*: 2020-04-07
    Sponsor Name:Das Kinderwunsch Institut Schenk GmbH
    Full Title: Oral and intravenous iron substitution for the treatment of iron deficiency symptoms in the context of fertility treatment - an exploratory pilot study
    Medical condition: infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003378-90 Sponsor Protocol Number: L00008CP402 Start Date*: 2006-12-20
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: TREAT STUDY : TREATMENT OF IRON DEFICIENCY ANAEMIA WITH TARDYFERON. Importance of prolonging iron supplementation in anemic women of childbearing age
    Medical condition: Iron Deficiency Anaemia is a common pathology which concerns less than 5% of women aged 15 to 49 years old in the western countries but can affect up to 30% of the world population, knowing that 9 ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001561-88 Sponsor Protocol Number: CICL670ATRO4 Start Date*: 2016-04-14
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation
    Medical condition: -Iron overload
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002037-11 Sponsor Protocol Number: IIISAS Start Date*: 2019-10-10
    Sponsor Name:Oslo University Hospital
    Full Title: Intravenous Iron supplement for Iron deficiency in patients with Severe Aortic Stenosis
    Medical condition: Iron deficiency, aortic stenosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10022971 Iron deficiencies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017737-21 Sponsor Protocol Number: IDNA 2009-01 Start Date*: 2011-01-18
    Sponsor Name:Vifor Pharma
    Full Title: A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficie...
    Medical condition: Treatment of iron deficient non anaemic women with ferric carboxymaltose.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022970 Iron deficiency LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003970-89 Sponsor Protocol Number: CICL670ADE02 Start Date*: 2007-12-21
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplan...
    Medical condition: allogeneic hematopoietic cell transplantation with iron overload
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001756 Allogenic bone marrow transplantation therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003202-27 Sponsor Protocol Number: FAST-TOT401-19 Start Date*: 2020-05-20
    Sponsor Name:Laboratoire Innotech Internationnal
    Full Title: Assessment of the eFficacy, the onset-of-Action and the Safety of Tot'héma ® in adults with moderate iron deficiency anaemia
    Medical condition: Moderate iron deficiency anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002062 Anaemia iron deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003598-33 Sponsor Protocol Number: LJ401-HH01 Start Date*: 2018-04-03
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A Phase 2, Multi-center, Randomized, Placebo-controlled, Single-blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004559-38 Sponsor Protocol Number: RG_12-101 Start Date*: 2012-08-08
    Sponsor Name:University of Birmingham
    Full Title: A phase 2 study of the efficacy and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent Myelodysplastic Syndromes.
    Medical condition: Iron overload in patients being treated for Myelodysplastic syndroms (MDS) by regular blood transfusions
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10068361 MDS LLT
    14.1 100000004848 10040310 Serum iron increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004322-42 Sponsor Protocol Number: CICL670A2402E1 Start Date*: 2017-08-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Efficacy and safety of long-term treatment with ICL670 in beta-thalassemia patients with transfusional hemosiderosis
    Medical condition: Tranfusional hemosiderosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003821-70 Sponsor Protocol Number: 1VIT18045 Start Date*: Information not available in EudraCT
    Sponsor Name:American Regent, Inc.
    Full Title: Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044
    Medical condition: Iron Deficiency Anemia (IDA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004008-10 Sponsor Protocol Number: CICL670AHU02 Start Date*: 2008-01-08
    Sponsor Name:Novartis Hungária Kft.
    Full Title: Evaluating the efficacy of Exjade® (deferasirox) in transfusion dependent chronic anaemias ( Myelodysplasia Syndrome, Beta-thalassaemia major patients) with chronic iron overload
    Medical condition: In- or outpatients with myelodysplasia or beta thalassaemia major, who have chronic iron overload, as a consequence of frequent blood transfusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003914-15 Sponsor Protocol Number: Studienprotokoll/V5.1/01.12.2013 Start Date*: 2014-06-17
    Sponsor Name:Medizinische Universität Wien, Klinik für Innere Medizin III, Klin. Abteilung für Nephrologie und Dialyse
    Full Title: Continuos versus periodic intravenous iron supplementation in maintenance hemodialysis patients
    Medical condition: Anemia and iron deficiency in patients with end-stage renal disease on maintenance dialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004147-37 Sponsor Protocol Number: 16-047 Start Date*: 2017-01-31
    Sponsor Name:Center for Translational & Clinical Research Aachen (CTC-A)
    Full Title: Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency: Effects upon phosphate and FGF23 metabolism
    Medical condition: Systolic heart failure (heart failure with reduced ejection fraction, HFREF) + iron deficiency with serum ferritin <100 μg/l or 100 – 299 μg/L when transferrin saturation (TSAT) is <20%
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000703-24 Sponsor Protocol Number: 1175-2017 Start Date*: 2017-11-17
    Sponsor Name:Medical University of Vienna; Department of Surgery; Division of Transplantation
    Full Title: Treatment of anemia with intravenous iron in patients listed for orthotopic liver transplantation
    Medical condition: iron deficiency anemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003461-17 Sponsor Protocol Number: 71272 Start Date*: 2020-01-07
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF)
    Medical condition: Heart failure with preserved ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001252-41 Sponsor Protocol Number: NA Start Date*: 2022-07-08
    Sponsor Name:CHU de Liège
    Full Title: Preventing postoperative anaemia in total knee arthroplasty and impact of intravenous iron supplementation on postoperative functional recovery : a randomized clinical trial
    Medical condition: Total Knee Arthroplasty
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 20:20:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA